Certus Pharma Spółka z Ograniczoną Odpowiedzialnością (KRS 0000565702, NIP 5732855011) is a Polish company, headquartered in Łódź, Łódzkie voivodeship. CERTUS PHARMA operates in: Dispensing chemist in specialised stores (PKD 47.73.Z). Industry: Retail trade. The company has been listed in the National Court Register since July 31, 2015. CERTUS PHARMA's most recently reported net revenue was 26.3 M PLN for 2024.
No arrears identified in the analyzed sources
No arrears or bankruptcy proceedings identified in the analyzed sources.
Business profile - Certus Pharma
Identity
- Name
- Certus Pharma Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Founded
- July 31, 2015
- Registry status as of
- May 10, 2026
- Latest entry
- May 10, 2026
- Founding act
- 11.06.2015R. NOTARIUSZ EWA SIWIŃSKA, KANCELARIA NOTARIALNA W KATOWICACH, REP. "A" NR 4246/2015
Articles of association history (3)
- June 11, 2015: 11.06.2015R. NOTARIUSZ EWA SIWIŃSKA, KANCELARIA NOTARIALNA W KATOWICACH, REP. "A" NR 4246/2015
- August 31, 2017: 31.08.2017 R., REP. "A" NR 7967/2017, NOTARIUSZ EWA SIWIŃSKA, KANCELARIA NOTARIALNA W KATOWICACH - ZMIENIONO § 3 UMOWY SPÓŁKI
- AKT NOTARIALNY Z DNIA 10 CZERWCA 2019 R. REP A NR 4028/2019 NOTARIUSZ BARTŁOMIEJ JANICKI KANCELARIA NOTARIALNA W ALEKSANDROWIE ŁÓDZKIM ZMIENIONO § 8 UST 3, § 13 UST 2, 18 UMOWY SPÓŁKI
Activities
Main activity
47.73.ZDispensing chemist in specialised stores
Other activities
General codes (divisions and groups)
General codes indicate a PKD division or group without a specific subclass.
Address and contact
- Address
- UL. KINGA C. GILLETTE, 11, 94-406, ŁÓDŹ, POLSKA
- Voivodeship
- ŁÓDZKIE
- District
- ŁÓDŹ
- Not disclosed in the registry
- Website
- Not disclosed in the registry
- E-delivery address
- AE:PL-26278-15214-TGBJF-15
- Coordinates
- 51.7768, 19.4547approx.
Risk and payment profile - Certus Pharma
Credibility rating
60.8 / 100
Good credibility
Insolvency risk
Very low
Low threat
Closure risk
1
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organizational stability signals
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
2
2/11 yrs
Board changes
1
1/11 yrs
PKD changes
0
0/11 yrs
Name changes
0
0/11 yrs
Data from 11 years of registry activity.
Credibility history
Payment reliability score from 2018–2024
Current: C (61/100)
Trend: deteriorating (-3.0 pts/year)
Moderate payment credibility - the company is able to meet its obligations, but some indicators warrant caution.
Trade credit limit history
Standard limit from 2018–2024
Current: 1.2 M PLN
Safe: 550.9 K PLN
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Operational status - Certus Pharma
Founded
July 31, 2015
10 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
ŁÓDŹ
ŁÓDZKIE
Primary PKD
47.73.Z
Dispensing chemist in specialised stores
Share capital
20.0 K PLN
200 shares total
Shareholders
2
shareholders
Board
3 people
Filed years
7 years
2018–2024
Registry entries
31
latest: May 10, 2026
Revenue
26.3 M PLN
2024
Net profit
912.9 K PLN
2024
Assets
7.5 M PLN
2024
Equity
2.1 M PLN
2024
EBITDA
974.4 K PLN
2024
Valuation
4.8 M PLN
High confidence
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - Certus Pharma.
No ratings
Related articles
News
Ambra in 2026: PLN 48.1 m capex (+212%), PLN 1.10 dividend three years running, Cydr Lubelski plus Romanian Zarea as the premium engine
Warsaw-based Ambra S.A. (KRS 0000041726, ul. Puławska 336) closed H1 of fiscal 2025/2026 with PLN 556.8 m of revenue and PLN 49.0 m of net profit, while raising capex by 212% to PLN 48.1 m - mainly for the soft-drinks line in Wola Duża and the PLN 11.9 m acquisition of a Romanian company. Despite the aggressive investment cycle the board keeps a PLN 1.10 dividend per share for the third year running (~5.9% yield).
News
Answear in 2026: first full year without MCI, PLN 9.3 m net profit, but the supervisory board cuts the 2026 EBITDA target from PLN 100 m to PLN 90 m
Kraków-based Answear.com S.A. (KRS 0000816066) closed 2025 with revenue of PLN 1.7 bn (+13% YoY), EBITDA of PLN 56 m (+63%) and net profit of PLN 9.3 m - a return to the black after a PLN 10 m loss in 2024. Poland grew +31%, but CEE was under FX pressure (hryvnia -11% vs PLN), and a weak Q4 (EBITDA -71% YoY) forced the supervisory board to cut the 2026 EBITDA target from PLN 100 m to PLN 90 m and the target price from PLN 50 to PLN 45. It is the first full year after MCI's exit from the shareholder base (10 June 2025); the Bajołek brothers retain control (57.8%).
